What is Fetal Fraction in NIPT? The Science Behind Accurate Results
If you've looked into NIPT (Non-Invasive Prenatal Testing), you've probably come across the term "fetal fraction." It sounds technical, but understanding it is key to understanding why NIPT works - and when it might not.
What is Fetal Fraction?
During pregnancy, fragments of DNA from the placenta circulate in the mother's bloodstream. This cell-free DNA (cfDNA) mixes with the mother's own cfDNA. Fetal fraction is simply the percentage of that circulating DNA that comes from the pregnancy rather than the mother.
For example, if a blood sample contains 10% fetal fraction, it means 10% of the cfDNA fragments originated from the placenta (and therefore reflect the baby's genetics), while 90% came from the mother.
Why Does Fetal Fraction Matter for NIPT?
NIPT works by analyzing cfDNA to detect chromosomal abnormalities like Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13). The test looks for subtle imbalances - slightly more DNA from chromosome 21, for instance, would suggest trisomy 21.
But here's the challenge: if fetal fraction is too low, the signal from the baby's DNA gets lost in the noise of the mother's DNA. Most labs require a minimum fetal fraction of 3-4% to report results reliably. Below that threshold, the test may return a "no call" or "insufficient fetal fraction" result.
What Affects Fetal Fraction?
Several factors influence fetal fraction:
Gestational age: Fetal fraction increases as pregnancy progresses. At 10 weeks (the earliest most labs will perform NIPT), fetal fraction averages around 10-15%. By 20 weeks, it can reach 20-30%.
Maternal weight: Higher maternal BMI is associated with lower fetal fraction. This is because mothers with higher body weight have more circulating maternal cfDNA, diluting the fetal signal.
Multiple pregnancies: Twin pregnancies have different fetal fraction dynamics. With identical twins sharing one placenta, fetal fraction is similar to singleton pregnancies. With fraternal twins, each placenta contributes separately, and the combined fetal fraction may be lower per fetus.
Biological variation: Even accounting for these factors, there's natural variation between pregnancies. Some pregnancies simply have higher or lower fetal fraction than others.
Low Fetal Fraction: What Happens Next?
If your NIPT returns with low fetal fraction, your provider will typically recommend one of two options:
Repeat testing: Waiting 1-2 weeks and retesting often works, as fetal fraction naturally increases with gestational age.
Alternative testing: Diagnostic testing like amniocentesis or CVS can provide definitive answers when NIPT isn't informative.
It's worth noting that persistently low fetal fraction - particularly very low levels - can occasionally be associated with placental abnormalities. Your healthcare provider will interpret results in the context of your specific pregnancy.
The Challenge for NIPT Development
For laboratories developing and validating NIPT assays, fetal fraction creates a fundamental challenge. Tests need to perform reliably across the full range of fetal fractions seen clinically - from 4% to 30% or more. But collecting real patient samples at specific fetal fractions, especially at the low end, is extremely difficult.
This is one reason why synthetic cfDNA technology is becoming important for NIPT validation. Synthetic samples can be generated at any desired fetal fraction, allowing laboratories to systematically validate performance across the full clinical range - something that's nearly impossible with patient-derived samples alone.
The Bottom Line
Fetal fraction is a critical quality metric for NIPT. It determines whether the test can reliably detect chromosomal abnormalities in your pregnancy. Understanding fetal fraction helps explain why NIPT has high accuracy in most cases, why some tests return inconclusive results, and why your provider might recommend waiting to retest or pursuing alternative testing options.
As prenatal screening technology continues to advance, addressing the fetal fraction challenge - both clinically and in test development - remains an active area of innovation.